Mizuho analyst Anthony Petrone initiated coverage of ResMed with a Buy rating and $255 price target. BMO’s sleep survey points to healthy underlying U.S. volumes and lingering pent-up demand due to staffing shortages, the analyst tells investors in a research note. The analyst says ResMed is a leader in digital health cloud-connected devices with "arguably the widest breadth" of solutions focused on respiratory conditions.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RMD:
- ResMed to Report Third Quarter Fiscal 2023 Earnings on April 27, 2023
- ResMed names Amy Wakeham chief communications and investor relations officer
- ResMed chief administrative officer, general counsel to retire
- ResMed Announces Participation in the 2023 KeyBanc Life Sciences & MedTech Investor Forum
- ResMed announces results of 2023 Global Sleep Survey
